Citadel Advisors’s Applied Therapeutics APLT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-57,700
| Closed | -$5.77K | – | 12920 |
|
|
2025
Q4 | $5.77K | Sell |
57,700
-25,900
| -31% | -$16.5K | ﹤0.01% | 12460 |
|
|
2025
Q3 | $50.6K | Sell |
83,600
-46,200
| -36% | -$21.8K | ﹤0.01% | 12201 |
|
|
2025
Q2 | $40.4K | Sell |
129,800
-8,600
| -6% | -$3.33K | ﹤0.01% | 11875 |
|
|
2025
Q1 | $67.7K | Sell |
138,400
-62,900
| -31% | -$37K | ﹤0.01% | 11962 |
|
|
2024
Q4 | $172K | Buy |
201,300
+87,400
| +77% | +$548K | ﹤0.01% | 10680 |
|
|
2024
Q3 | $968K | Buy |
113,900
+22,300
| +24% | +$131K | ﹤0.01% | 6928 |
|
|
2024
Q2 | $428K | Sell |
91,600
-28,000
| -23% | -$132K | ﹤0.01% | 8378 |
|
|
2024
Q1 | $813K | Buy |
119,600
+55,100
| +85% | +$247K | ﹤0.01% | 7371 |
|
|
2023
Q4 | $216K | Buy |
64,500
+34,000
| +111% | +$84.6K | ﹤0.01% | 9797 |
|
|
2023
Q3 | $75.9K | Buy |
30,500
+17,100
| +128% | +$28.2K | ﹤0.01% | 11232 |
|
|
2023
Q2 | $17.2K | Buy |
+13,400
| New | +$17.8K | ﹤0.01% | 12861 |
|
|
2023
Q1 | – | Sell |
-35,700
| Closed | -$27.1K | – | 14663 |
|
|
2022
Q4 | $27.1K | Buy |
35,700
+13,500
| +61% | +$10.7K | ﹤0.01% | 12860 |
|
|
2022
Q3 | $21K | Buy |
+22,200
| New | +$26.6K | ﹤0.01% | 12051 |
|
|
2022
Q1 | – | Sell |
-54,100
| Closed | -$484K | – | 13511 |
|
|
2021
Q4 | $484K | Buy |
54,100
+28,700
| +113% | +$377K | ﹤0.01% | 9774 |
|
|
2021
Q3 | $422K | Buy |
+25,400
| New | +$439K | ﹤0.01% | 10285 |
|
|
2021
Q2 | – | Sell |
-13,300
| Closed | -$249K | – | 13612 |
|
|
2021
Q1 | $249K | Buy |
+13,300
| New | +$287K | ﹤0.01% | 11238 |
|
Citadel Advisors's APLT Position: Q3 2025 in Review
Citadel Advisors sold out of Applied Therapeutics (APLT) in Q3 2025, closing a stake of 474,094 shares — an estimated $223K sold.
Citadel Advisors first reported a position in APLT in Q1 2020 and held it in 15 quarters. The position peaked at $3M in Q3 2024. 70 funds tracked by Wall St. Rank hold APLT as of Q3 2025.
- Citadel Advisors reported no remaining Applied Therapeutics position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 474,094 Applied Therapeutics shares in Q3 2025, an estimated $223K.
- Citadel Advisors first reported a position in Applied Therapeutics in Q1 2020 and held it in 15 quarters.
- Citadel Advisors's Applied Therapeutics position peaked at $3M in Q3 2024.
- 70 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.